Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
1.5K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

148
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
148
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

4.6K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic Modification as a Regulatory Mechanism for Spatiotemporal Dynamics of ANO1 Expression in Salivary Glands.

International journal of molecular sciences·2019
Same author

Tissue Distribution of Kir7.1 Inwardly Rectifying K<sup>+</sup> Channel Probed in a Knock-in Mouse Expressing a Haemagglutinin-Tagged Protein.

Frontiers in physiology·2018
Same author

Reply to Orešković et al.

Physiological reviews·2016
Same author

Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.

Cancer chemotherapy and pharmacology·2014
Same author

Effects of octane derivatives on activity of the volume-regulated anion channel in rat pancreatic β-cells.

Pharmacological reports : PR·2014
Same author

Cerebrospinal fluid secretion by the choroid plexus.

Physiological reviews·2013
Same journal

Engineering Functional Graphenic Materials for Bone Repair.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026
Same journal

Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026
Same journal

Advances in Engineered Virus-Like Particles for Applications in Nanomedicine.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026
Same journal

Lipid- and Polymer-Based Nanoscale Delivery of Anti-Aging Phytochemicals.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026
Same journal

Nano-Enabled Toxicity of Pharmaceutical Excipients.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026
Same journal

Advances in Self-Assembly Artificial Chaperone for Protein Folding Regulation.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026
See all related articles

Related Experiment Video

Updated: Apr 24, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

8.2K

Nanomedicine: a pharma perspective.

Peter D Brown1, Piyush R Patel

  • 1Teva Pharmaceuticals, Frazer, PA, USA.

Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
|September 9, 2014
PubMed
Summary
This summary is machine-generated.

Nanomedicines, using nanoparticle drug delivery systems, have evolved since the 1970s. Despite early challenges, ongoing research in nanomedicine promises significant therapeutic advancements.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

12.3K

Related Experiment Videos

Last Updated: Apr 24, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

8.2K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

12.3K

Area of Science:

  • Medical nanotechnology
  • Pharmaceutical sciences
  • Drug delivery systems

Background:

  • Nanomedicine research began in the 1970s with liposomal formulations showing promise in preclinical studies.
  • Early nanomedicines demonstrated improved drug efficacy and reduced toxicity but faced challenges in clinical translation.
  • Limited pharmaceutical investment in nanomedicines was due to subtle patient benefits and production hurdles.

Purpose of the Study:

  • To review the historical development and current status of nanomedicine.
  • To highlight advancements in nanoparticle design and drug combinations.
  • To assess the future potential of nanomedicines in clinical practice.

Main Methods:

  • Review of historical research and development in nanomedicine.
  • Analysis of challenges in clinical translation and commercial production.
  • Examination of ongoing research in academic and biopharmaceutical settings.

Main Results:

  • Initial nanomedicines (liposomal formulations) showed therapeutic benefits in preclinical models.
  • Clinical translation of nanomedicines has been slower than anticipated due to various factors.
  • Significant research continues with new materials, drug combinations, and targeting strategies.

Conclusions:

  • Despite past challenges, nanomedicine research is advancing with novel designs nearing clinical trials.
  • Successful clinical outcomes for new nanomedicines could revitalize pharmaceutical investment.
  • The field of nanomedicine holds significant potential for future therapeutic innovation.